Bayer (FRA:BAYN) has been given a €99.00 ($115.12) price target by stock analysts at Commerzbank in a research report issued on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Commerzbank’s target price would suggest a potential upside of 39.44% from the stock’s previous close.
A number of other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. reissued a “buy” rating on shares of Bayer in a research report on Thursday, August 30th. Berenberg Bank set a €113.00 ($131.40) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Monday, August 27th. Deutsche Bank set a €130.00 ($151.16) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Monday, September 3rd. Jefferies Financial Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, October 11th. Finally, UBS Group set a €122.00 ($141.86) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, October 4th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of €96.88 ($112.65).
Shares of FRA BAYN opened at €71.00 ($82.56) on Thursday. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.